Aeterna Zentaris, Inc.
AEZS
AEZS: AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.
moreShow AEZS Financials
Recent trades of AEZS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by AEZS's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Method of assessing growth hormone deficiency in humans by a macimorelin containing composition May. 14, 2019
-
Patent Title: Application of initial doses of lhrh analogues and maintenance doses of lhrh antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits Dec. 30, 2014
-
Patent Title: Pyridopyrazine derivatives and their use Dec. 16, 2014
-
Patent Title: Pyridopyrazines as highly selective ras-raf-mek-erk signal transduction pathway inhibitors Jul. 29, 2014
-
Patent Title: Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof Mar. 25, 2014
-
Patent Title: Prohibitin as target for cancer therapy Feb. 25, 2014
-
Patent Title: Modulating signal transduction pathways with 1-ethyl-3-[3-(1-methyl-1h-pyrazol-4-yl)-pyrido[2.3-b]pyrazine-6-yl]thiourea Dec. 10, 2013
-
Patent Title: Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals Oct. 08, 2013
-
Patent Title: Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors Oct. 01, 2013
-
Patent Title: Tetrahydrocarbazole derivatives as ligands of g-protein coupled receptors Sep. 24, 2013
-
Patent Title: Modulating signal transduction pathways with substituted pyridol [2,3-b] pyrazines Sep. 17, 2013
-
Patent Title: Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals Aug. 13, 2013
-
Patent Title: Pyridopyrazine derivatives, process of manufacturing and uses thereof Aug. 13, 2013
-
Patent Title: Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof Jun. 25, 2013
-
Patent Title: Naphthyridine derivatives and the use thereof as kinase inhibitors Jun. 11, 2013
-
Patent Title: Quinoxaline derivatives and their use for treating benign and malignant tumour disorders Mar. 12, 2013
-
Patent Title: Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals Mar. 05, 2013
-
Patent Title: Perifosine and capecitabine as a combined treatment for cancer Feb. 26, 2013
-
Patent Title: Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals Feb. 26, 2013
-
Patent Title: Substituted pyrido[2,3-b]pyrazine compounds as modulators of tyrosine kinases Jun. 19, 2012
-
Patent Title: Pyridopyrazines and the use thereof as kinase inhibitors Jun. 05, 2012
-
Patent Title: Methods and kits to diagnose growth hormone deficiency by oral administration of ep 1572 or ep 1573 compounds Jun. 05, 2012
-
Patent Title: Tetrahydrocarbazole derivatives as ligands of g-protein coupled receptors Apr. 03, 2012
-
Patent Title: Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of g-protein coupled receptors (gpcps) Nov. 29, 2011
-
Patent Title: Indole derivatives and their use as medicament Aug. 30, 2011
-
Patent Title: Indole derivatives and their use as medicament Aug. 02, 2011
-
Patent Title: Process for preventing protozoal diseases Feb. 15, 2011
-
Patent Title: Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof Jun. 22, 2010
-
Patent Title: Pharmaceutical administration form for peptides, process for its preparation, and use May. 18, 2010
-
Patent Title: Pharmaceutical administration form for peptides, process for its preparation, and use Apr. 13, 2010
Federal grants, loans, and purchases
Followers on AEZS's company Twitter account
Number of mentions of AEZS in WallStreetBets Daily Discussion
Recent insights relating to AEZS
Recent picks made for AEZS stock on CNBC
ETFs with the largest estimated holdings in AEZS
Flights by private jets registered to AEZS